A comparison of multidrug-resistant tuberculosis treatment commencement times in MDRTBPlus line probe assay and Xpert® MTB/RIF-based algorithms in a routine operational setting in Cape Town

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Naidoo, Pren ^a   Du Toit, Elizabeth ^a   Dunbar, Rory ^a   Lombard, Carl ^b   Caldwell, Judy ^c   Detjen, Anne ^d   Squire, S Bertel ^e   Enarson, Donald A ^d   Beyers, Nulda ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c Cape Town City Health Department   (South Africa)

^d INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^e LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ALGORITHM; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL LOAD; DIAGNOSTIC TEST; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; INTERMETHOD COMPARISON; LINE PROBE ASSAY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OBSERVATIONAL STUDY; PRIMARY HEALTH CARE; SCREENING TEST; SOUTH AFRICA; SPUTUM SMEAR; TUBERCULOSIS RAPID TEST; COMPARATIVE STUDY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ALGORITHMS; ANTITUBERCULAR AGENTS; HUMANS; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84905408470     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103328     Document Type: Article

References (29)

1. World Health Organisation (2010) Multidrug and extensively drug-resistant TB (M/XDR-TB), 2010 Global Report on Surveillance and Response.
2. Hoek KGP, Rie VA, van Helden PD, Warren RM, Victor TC (2011) Detecting Drug-Resistant Tuberculosis. Mol Diagn Ther 15: 189-194.
3. Pai M, Minion J, Sohn H, Zwerling A, Perkins MD (2009) Novel and improved technologies for tuberculosis diagnosis: progress and challenges. Clin Chest Med 30: 701-16.
4. World Health Organisation (2012) Global Tuberculosis Report 2012. Elsevier.
5. World Health Organisation (2008) Molecular Line Probe Assays For Rapid Screening Of Patients At Risk Of Multidrug-Resistant Tuberculosis. Policy Statement.
6. World Health Organisation (2011) Automated Real-time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System. Policy Statment.
7. Miotto P, Piana F, Cirillo DM, Migliori GB (2008) Genotype MTBDRplus: a further step toward rapid identification of drug-resistant Mycobacterium tuberculosis. J Clin Microbiol 46: 393-394.
8. Hillemann D, Rüsch-Gerdes S, Richter E (2007) Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 45: 2635-2640. (Pubitemid 47295497)
9. Hillemann D, Rüsch-Gerdes S, Richter E (2006) Application of the Genotype MTBDR assay directly on sputum specimens. Int J Tuberc Lung Dis 10: 1057-1059. (Pubitemid 44378986)
10. Helb D, Jones M, Story E, Boehme C, Wallace E, et al. (2010) Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 48: 229-237.
11. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, et al. (2010) Rapid Molecular Detection of Tuberculosis and Rifampicin Resistance. NEJM 363: 1005-1015.
12. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, et al. (2011) Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377: 1495-1505.
13. Ling DI, Zwerling AA, Pai M (2008) GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 32: 1165-1174.
14. Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, et al. (2013) Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults (Review). Cochrane Collab. Available: http://onlinelibrary.wiley.com/doi/ 10.1002/14651858.CD009593.pub2/pdf/standard. Accessed 2013 Aug 11.
15. Chang K, Lu W, Wang J, Zhang K, Jia S, et al. (2012) Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J Infect 64: 580-588.
16. Pai M, Minion J, Steingart K, Ramsay A (2010) New and improved tuberculosis diagnostics: evidence, policy, practice, and impact. Curr opin pulm med Vol. 16(3): 271-84.
17. World Health Organisation (2008) Molecular Line Probe Assays For Rapid Screening Of Patients At Risk Of Multidrug-Resistant Tuberculosis. Expert Group Report.
18. Jacobson KR, Theron D, Kendall EA, Franke MF, Barnard M, et al. (2013) Implementation of genotype MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa. Clin Infect Dis 56: 503-508.
19. Narasimooloo R, Ross A (2012) Delay in commencing treatment for MDR TB at a specialised TB treatment centre in KwaZulu-Natal. S Afr Med J 102: 360-362.
20. Hanrahan CF, Selibas K, Deery CB, Dansey H, Clouse K, et al. (2013) Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One 8: e65421. Available: http://www.pubmedcentral.nih.gov/ articlerender.fcgi?artid=3675091&tool=pmcentrez&rendertype=abstract. Accessed 2013 Aug 19.
21. Mann G, Squire SB, Bissell K, Eliseev P, Toit E Du, et al. (2010) Beyond accuracy: creating a comprehensive evidence base for tuberculosis diagnostic tools. IJTLD 14: 1518-1524.
22. Sedgwick P, Joekes K (2011) Survival (time to event) data: median survival times. BMJ 343: d4890-d4890. Available: http://www.bmj.com/cgi/doi/10. 1136/bmj.d4890. Accessed 2014 Jun 12.
23. Yagui M, Perales MT, Asencios L, Vergara L, Suarez C, et al. (2006) Timely diagnosis of MDR-TB under program conditions: is rapid drug susceptibility testing sufficient? Int J Tuberc Lung Dis 10: 838-843. (Pubitemid 44197842)
24. van Niekerk M, Leon N, du Toit E, Beyers N, Naidoo P (2013) Patients' experiences of accessing MDR-TB diagnosis and treatment in the Xpert MTB/RIF era in Cape Town, South Africa. 44th Union World Conference on Lung Health, 30 October-3 November 2013, Paris.
25. Ebonwu JI, Tint KS, Ihekweazu C (2013) Low treatment initiation rates among multidrug-resistant tuberculosis patients in Gauteng, South Africa, 2011. Int J Tuberc Lung Dis 17: 1043-1048.
26. Meyer-Rath G, Schnippel K, Long L, Macleod W, Sanne I, et al. (2012) The Impact and Cost of Scaling up GeneXpert MTB/RIF in South Africa. PlosOne 7: e36966. doi:10.1371/journal.pone.0036966. Accessed 2012 Oct 30.
27. World Health Organisation (2009) Pathways to better diagnostics for tuberculosis: a blueprint for the development of TB diagnostics by the new diagnostics working group of the Stop TB Partnership.
28. South African National AIDS Council (2012) National Strategic Plan on HIV, STIs and TB 2012-2016.
29. Nathanson E, Nunn P, Uplekar M (2010) MDR tuberculosis-critical steps for prevention and control. N Engl J Med 363: 1050-1058.